Find the lowest price from 7,500+ FDA-registered pharmacies. Save up to 90%.
⭐ 4.7/5 Customer Rating
🏅 FDA-Registered Pharmacies
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
Blocks histamine H1 receptors directly at target tissues — a second line of action that manages symptoms even when some mediator release occurs.
Compounded pergolide oral suspension is the most affordable and practical treatment for horses with PPID (equine Cushing's disease) — a fraction of the cost of commercial Prascend tablets with easier administration.
Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Pergolide is a dopamine agonist that reduces excess ACTH production from the pituitary, controlling symptoms of PPID in horses.
Commercial Prascend tablets are significantly more expensive than compounded pergolide. Oral paste or suspension formulations are far easier to administer to horses than tablets.
Pituitary Pars Intermedia Dysfunction (PPID), commonly called equine Cushing's disease, is the most common endocrine disorder in older horses and ponies. It is caused by a dysfunction of dopaminergic neurons that normally suppress the pars intermedia of the pituitary gland, leading to excessive ACTH and other hormone production.
Pergolide mesylate is the only FDA-approved treatment for equine PPID (as Prascend tablets), but at $3–5 per tablet, costs can be prohibitive for long-term management. Compounded pergolide oral suspension or paste is significantly more affordable and easier to administer to horses who resist tablet administration.
Pergolide is a dopamine D1 and D2 receptor agonist. In horses with PPID, the loss of dopaminergic innervation to the pars intermedia allows unchecked proliferation and hormonal output. Pergolide restores dopaminergic inhibition, reducing ACTH, alpha-MSH, and other pro-opiomelanocortin (POMC)-derived peptides to more normal levels.
Clinical improvement in PPID signs (hypertrichosis, laminitis risk, muscle wasting) typically occurs within 1–3 months of initiating effective therapy.
Compounded pergolide is used in horses for PPID (equine Cushing's disease), indicated by elevated ACTH levels, hypertrichosis (failure to shed coat), polyuria/polydipsia, muscle wasting, and increased susceptibility to laminitis. It is a lifelong treatment in most affected horses.
BIND THIS TO: Mechanism Text CMS field (Rich Text). Then delete this paragraph and add a Rich Text element instead.
⚠️ Dosing should be determined by your prescriber. The information below is general guidance only.
The most common side effect at initiation is anorexia (reduced appetite), which typically resolves within 1–2 weeks. Starting at a lower dose and titrating up over several weeks minimizes this effect. Rare side effects include mild neurologic signs at high doses.
Regular ACTH monitoring (every 6 months, or seasonally) is recommended to guide dose adjustment, as ACTH levels rise naturally in autumn in horses.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
